140 related articles for article (PubMed ID: 33904018)
1. In vitro cytotoxic effect of a chitin-like polysaccharide produced by Mortierella alpina on adrenocortical carcinoma cells H295R, and its use as mitotane adjuvant.
Goyzueta Mamani LD; de Carvalho JC; Bonatto SJR; Tanobe VAO; Soccol CR
In Vitro Cell Dev Biol Anim; 2021 Apr; 57(4):395-403. PubMed ID: 33904018
[TBL] [Abstract][Full Text] [Related]
2. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
[TBL] [Abstract][Full Text] [Related]
3. Production, characterization, and biological activity of a chitin-like EPS produced by Mortierella alpina under submerged fermentation.
Goyzueta M LD; Noseda MD; Bonatto SJR; de Freitas RA; de Carvalho JC; Soccol CR
Carbohydr Polym; 2020 Nov; 247():116716. PubMed ID: 32829843
[TBL] [Abstract][Full Text] [Related]
4. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
[TBL] [Abstract][Full Text] [Related]
5. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
[TBL] [Abstract][Full Text] [Related]
6. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
7. The effects of mitotane and 1α,25-dihydroxyvitamin D
Rubin B; Pilon C; Pezzani R; Rebellato A; Fallo F
J Endocrinol Invest; 2020 Mar; 43(3):357-367. PubMed ID: 31587178
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells.
Abate A; Rossini E; Tamburello M; Laganà M; Cosentini D; Grisanti S; Fiorentini C; Tiberio GAM; Scatolini M; Grosso E; Hantel C; Memo M; Berruti A; Sigala S
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34875044
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
11. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
[TBL] [Abstract][Full Text] [Related]
12. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
Cerquetti L; Sampaoli C; Amendola D; Bucci B; Misiti S; Raza G; De Paula U; Marchese R; Brunetti E; Toscano V; Stigliano A
Int J Oncol; 2010 Aug; 37(2):493-501. PubMed ID: 20596677
[TBL] [Abstract][Full Text] [Related]
13. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
14. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
[TBL] [Abstract][Full Text] [Related]
15. Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC.
Warde KM; Schoenmakers E; Ribes Martinez E; Lim YJ; Leonard M; Lawless SJ; O'Shea P; Chatterjee KV; Gurnell M; Hantel C; Dennedy MC
Endocr Relat Cancer; 2020 Jun; 27(6):361-373. PubMed ID: 32276262
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
Germano A; Rapa I; Volante M; Lo Buono N; Carturan S; Berruti A; Terzolo M; Papotti M
Mol Cell Endocrinol; 2014 Jan; 382(1):1-7. PubMed ID: 24018612
[TBL] [Abstract][Full Text] [Related]
17. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
[TBL] [Abstract][Full Text] [Related]
18. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
[TBL] [Abstract][Full Text] [Related]
19. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
Warde KM; Lim YJ; Ribes Martinez E; Beuschlein F; O'Shea P; Hantel C; Dennedy MC
Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35797592
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.
Sbiera S; Kendl S; Weigand I; Sbiera I; Fassnacht M; Kroiss M
Mol Cell Endocrinol; 2019 Jan; 480():36-41. PubMed ID: 30315857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
